May be taken with or without food. Incidence of minor indigestion may increase as dose increases. Take w/ meals if necessary.
|
Undiagnosed vaginal bleeding, previous idiopathic or current venous thromboembolism (e.g. DVT, pulmonary embolism); active or recent arterial thromboembolic disease (e.g. angina, MI) or cerebrovascular disease; missed abortion. Gynaecological/contraceptive use: Known, history or suspected breast cancer; porphyria; metabolic bone disease (SC). Hepatic impairment. Pregnancy.
|
Patient with risk factors for estrogen-dependent tumours; history of or risk factors for thromboembolic disorders; hypertension, liver disorders (e.g. liver adenoma), cholelithiasis, history of liver disease, diabetes mellitus (with or without vascular involvement), migraine or severe headache, SLE, epilepsy, asthma, otosclerosis, cardiac dysfunction, history of acute visual disturbances or mental depression, hypercholesterolaemia; hypoparathyroidism (in combination with estrogen). Obesity. Risk factors for osteoporosis (e.g. chronic alcohol or tobacco use, low BMI, eating disorder, previous low trauma fracture, family history of osteoporosis). Renal impairment. Lactation. Discontinue combination therapy with estrogens at least 4-6 weeks prior to surgery associated with an increased risk of thromboembolism or within periods of prolonged immobilisation. Monitoring Parameters Obtain bone mineral density (prolonged use). Monitor blood pressure and glucose (in diabetic patients). Evaluate for vision loss, migraines, signs of thromboembolic disorders or depression. Contraceptive use: Verify pregnancy status prior to use. Monitor weight and assess potential health status changes.
|
Significant: Decreased glucose tolerance, jaundice, increased blood pressure, new onset of migraine-type headache, weight gain, fluid retention; vaginal bleeding, depression, menstrual irregularities (e.g. amenorrhoea, unpredictable bleeding or spotting), Cushingoid symptoms, suppressed adrenal function, increased triglycerides (in women with pre-existing hypertriglyceridaemia), visual abnormalities, thromboembolic disorders, loss of bone mineral density, delayed return to ovulation and fertility (upon discontinuation), anaphylaxis or anaphylactoid reaction, severe abdominal pain (IM/SC).
Gastrointestinal disorders: Nausea, vomiting, constipation; abdominal pain, distension, or discomfort.
General disorders and administration site conditions: Pyrexia, fatigue; asthenia, inj site reaction (SC).
Investigations: Weight decreased; abnormal smear cervix (SC).
Metabolism and nutrition disorders: Hypercalcaemia (in treatment of breast carcinoma), increased appetite.
Musculoskeletal and connective tissue disorders: Back pain, pain in extremity.
Nervous system disorders: Headache, dizziness, tremors.
Psychiatric disorders: Insomnia, nervousness, libido decreased.
Reproductive system and breast disorders: Cervical discharge, breast pain or tenderness, erectile dysfunction, dysmenorrhea, genitourinary tract infection.
Skin and subcutaneous tissue disorders: Urticaria, alopecia, acne, pruritus, hyperhidrosis.
Vascular disorders: Hot flush.
|
|
|
Bioavailability may be decreased when used concomitantly with aminoglutethimide. May decrease plasma concentration with enzyme inducers including CYP3A4 (e.g. phenytoin, phenobarbital, carbamazepine, rifampicin, nevirapine). Concomitant use with ciclosporin may result in increased plasma levels of ciclosporin and/or decreased plasma levels of medroxyprogesterone. May decrease the haematological toxicity of cytotoxic agents. Increased risk of invasive breast cancer, dementia, and CV disease (e.g. DVT, pulmonary emboli, stroke) in postmenopausal women when used concomitantly with conjugated estrogens.
|
|
|
L02AB02 - medroxyprogesterone ; Belongs to the class of progestogens.
G03AC06 - medroxyprogesterone ; Belongs to the class of progestogens. Used as systemic contraceptives.
G03DA02 - medroxyprogesterone ; Belongs to the class of pregnen (4) derivative progestogens.
|
Sign Out
